Xenon Pharmaceuticals Inc

XENE

Healthcare|Biotechnology|Canada

$68.94

-2.05 (-2.89%)

Tangible Book

$13.85

Clinical Trials (23)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06775379 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder	Major Depressive Disorder	P3	Recruiting	450	RCT, Double-blind	Azetukalner, Placebo
NCT07172516 A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)	Bipolar Disorder, Bipolar Depression	P3	Recruiting	400	RCT, Double-blind	Azetukalner, Placebo
NCT05667142 A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures	Primary Generalized Tonic-Clonic Seizures	P3	Recruiting	160	RCT, Double-blind	XEN1101, Placebo
NCT05716100 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)	Focal Onset Seizures	P3	Recruiting	360	RCT, Double-blind	XEN1101, Placebo
NCT07076407 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)	Major Depressive Disorder	P3	Recruiting	450	RCT, Double-blind	Azetukalner, Placebo
NCT03796962 A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy	Focal Epilepsy	P2	Active	325	RCT, Double-blind	XEN1101
NCT05718817 An Open-label Study of XEN1101 in Epilepsy	Focal Epilepsy, Tonic-Clonic Seizures	P3	By Invite	880	Open-label	XEN1101
NCT07217860 An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)	Bipolar Depression, Bipolar I Disorder	P3	By Invite	400	Open-label	Azetukalner
NCT04912856 An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE	Epilepsy, Epilepsy in Children	P3	Terminated	8	Double-blind	XEN496
NCT05614063 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures	Focal Onset Seizures	P3	Completed	380	RCT, Double-blind	XEN1101, Placebo
NCT06922110 An Open-Label Study of Azetukalner in Major Depressive Disorder	Major Depressive Disorder	P3	By Invite	460	Open-label	Azetukalner
NCT04639310 XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy	Epilepsy, Epilepsy in Children	P3	Terminated	8	RCT, Double-blind	XEN496, Placebo
NCT05376150 A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder	Major Depressive Disorder	P2	Completed	168	RCT, Double-blind	XEN1101 10 mg, XEN1101 20 mg, Placebo
NCT01195636 A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)	Postherpetic Neuralgia	P2	Completed	70	RCT, Double-blind	XPF-002, Placebo
NCT00954356 Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction	Dental Pain	P2	Completed	61	RCT, Double-blind	XPF-001, placebo
NCT01486446 Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia	Primary Erythromelalgia, Inherited Erythromelalgia	P1P2	Completed	8	RCT, Double-blind	XPF-002, Placebo
NCT01090622 Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)	Primary Erythromelalgia, Inherited Erythromelalgia	P1P2	Completed	4	RCT, Double-blind	XPF-001, Placebo
NCT02656043 A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel	Acne Vulgaris	P1P2	Completed	213	RCT, Double-blind	XPF-005, Placebo
NCT03468725 Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101	Healthy Male Volunteers	P1	Completed	20	RCT, Double-blind	XPF-008, Microcrystalline Cellulose
NCT00813670 Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers	Healthy Human Volunteers	P1	Completed	64	RCT, Double-blind	XPF-001
NCT04952467 Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101	Healthy Volunteers	P1	Completed	6	Open-label	14C-XEN1101
NCT03467100 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901	Healthy Volunteers	P1	Completed	70	RCT, Double-blind	XEN901, Inert Ingredients Oral Product
NCT03340220 Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.	Healthy Volunteers	P1	Completed	130	Double-blind	XPF-008, Microcrystalline Cellulose, XPF-010, Itraconazole 400mg